Home World News Efficacy of Talquetamab Plus Teclistamab in Patients with Extramedullary Myeloma World News Efficacy of Talquetamab Plus Teclistamab in Patients with Extramedullary Myeloma By Ogkologos - December 10, 2025 618 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the phase II cohort of the RedirecTT-1 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Veteran Drops To The Ground When He Hears How Much His... January 31, 2020 Bride Learns Sign Language, Surprises Groom’s Deaf Parents & Signs Her... January 11, 2022 FDA Grants Accelerated Approval to Tafasitamab-cxix for DLBCL August 7, 2020 Abiraterone Acetate Plus Prednisone and LHRH Analogue is Active and Safe... October 4, 2021 Load more HOT NEWS Ahead of key Competitiveness Council Meeting of European Research Ministers, ESMO... Pyrotinib in HER2-mutated Advanced NSCLC Previously Treated with Chemotherapy Health inequalities: Why do people smoke if they know it’s bad... “Things Are Shrinking” Says Olivia Newton-John About Her Stage IV Breast...
